Does an anti-GPVI antibody reduce infarct size in myocardial ischemia-reperfusion injury?
Inhibition of platelet GPVI reduces infarct size and improves microperfusion in myocardial ischemia-reperfusion injury, highlighting a potential novel therapeutic target.
Inhibition of platelet activation by an anti-GPVI antibody, but not inhibition of platelet adhesion or aggregation by an anti-GPIb or anti-GPIIbIIIa antibody significantly reduces infarct size. The reduction of the infarct size is primarily based on an improved microperfusion after anti-GPVI antibody treatment.
Pachel et al. (Fri,) studied this question.